Table 3.
Variables associated with COVID-19 progression*
| Progressed N = 21 (%) | Did not progress N = 79 (%) | P value | |
|---|---|---|---|
| Median age in years (IQR) | 56 (52–64) | 48 (31–60) | 0.018 |
| Men | 13 (20.6) | 50 (79.4) | 0.907 |
| Women | 8 (21.6) | 29 (78.4) | |
| At least one comorbidity | 9 (25.7) | 26 (74.3) | 0.397 |
| No comorbidities | 12 (18.5) | 53 (81.5) | |
| Two or more vaccine doses | 12 (19.7) | 49 (80.3) | 0.868 |
| Less than two vaccine doses | 8 (21) | 30 (79) | |
| Chemotherapy < 30 days | 14 (29.2) | 34 (70.8) | 0.054 |
| Chemotherapy > 30 days | 7 (13.5) | 45 (86.5) | |
| Time from rituximab to onset of symptoms, in days (IQR) | 25 (6.5–64) | 58 (20–160) | 0.077 |
| Neoplasia in remission | 0 (0) | 18 (100) | 0.016 |
| Active neoplasia | 21 (25.6) | 61 (74.4) | |
| Clinical stage at diagnosis | |||
| Mild | 5 (8.3) | 55 (91.7) | < 0.001 |
| Moderate | 6 (54.6) | 5 (45.4) | |
| Severe | 10 (34.5) | 19 (65.5) | |
| Rituximab | 16 (32) | 34 (68) | 0.007 |
| No rituximab | 5 (10) | 45 (90) | |
| Hospital admission at COVID-19 | 12 (35.3) | 22 (74.7) | 0.012 |
| Diagnosis ambulatory at COVID-19 diagnosis | 9 (13.6) | 57 (86.4) | |
| Hospital admission for Non-COVID causes | |||
| Yes | 7 (41.2) | 10 (58.8) | 0.025 |
| No | 14 (16.9) | 69 (83.1) | |
| Remdesivir | 8 (30.8) | 18 (69.2) | 0.155 |
| No remdesivir | 13 (17.6) | 61 (82.4) | |
*Asymptomatic and critical cases are excluded